openPR Logo
Press release

Oncology Drug Pipeline Analysis Market Set Explosive Growth to 2026 By Key Companies F. Hoffmann-La Roche, Bristol-Myers Squibb, Johnson & Johnson, AstraZeneca

05-30-2019 09:25 AM CET | Health & Medicine

Press release from: Coherent Market Insights - Pharmaceutical Industry

Oncology Drug Pipeline Analysis

Oncology Drug Pipeline Analysis

Oncology Drug Pipeline Analysis – Challenges

Increasing cost of therapies is expected to hinder growth of the oncology drug pipeline market. For instance, according to a report published in National Center for Biotechnology Information (NCBI), 2016, Pertuzumab-based therapy, used in treatment of HER2 positive breast cancer costs US$ 215,000 per patient.

Ask For The Highly Informative Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2184

Moreover, lack of patient’s participation in clinical studies, increase in clinical trial complexity, and resource constraints are some of the other factors hampering growth of the oncology drug pipeline market. For instance, according to a report published in Journal of Clinical oncology, June 2012, the rate of number of cancer patients enrolling in clinical trial worldwide is 3%-5% and the rate has not improved since 1980.

Oncology Drug Pipeline Analysis – Regional Analysis

On the basis of region, the global oncology drug pipeline analysis market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to dominate in terms of growth in oncology drug pipeline market. According to the 2015 annual report of the American Cancer Society, although cancer-related death rate in the U.S. have reduced, cancer still remains the second most common cause of death in the country. Therefore, such high prevalence of cancer is expected to drive growth of the oncology drug pipeline market in North America.

Asia Pacific is expected to witness significant growth in the global oncology drug pipeline analysis market. This is owing to increasing prevalence of various kind of cancers in the region, especially in emerging economies such as China and India.

Furthermore, key players are focused on establishing manufacturing facility in Asia Pacific. For instance, in September 2018, BeiGene Co.Ltd. —a commercial-stage biotechnology company, selected GE Healthcare’s bio manufacturing facility— KUBio, for large-scale production of its cancer monoclonal antibodies in China.

Key players operating in the global oncology pipeline drugs market include, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., AstraZeneca, Pfizer Inc., AbbVie Inc., Celgene Corporation, Novartis AG, Merck & Co., Inc., Sanofi, Eli Lilly & Co., GlaxoSmithKline, and Amgen Inc.

Oncology Drug Pipeline Analysis – Drivers

Innovative approaches in the cancer treatment is a major factor boosting growth of the oncology pipeline drugs market. For instance, the novel basket study includes patients with a certain genetic mutation in common, regardless of the site or origin of cancer in the body. Basket studies can be useful when a drug targets certain genetic mutation at a particular site and using that drug to treat same genetic mutation in cancer at another site. For instance, Larotrectinib, a drug of Loxo Oncology, Inc., is currently under review by the U.S. FDA for the treatment of tyrosine kinase mutation by using basket studies. This drug has been approved as Investigational New Drug in May 2018.

Request Customization @ https://www.coherentmarketinsights.com/insight/request-customization/2184

Combinational therapies are the latest development driving the growth of oncology pipeline drugs market. For instance, Pfizer Inc. is undergoing efficacy and safety study for Avelumab in combination with chemotherapy, followed by maintenance therapy of Avelumab with PARP inhibitor talazoparib in patients with history of untreated advanced ovarian cancer. This study is under clinical phase III trials and is expected to complete in May 2026.

Furthermore, increasing government investment to support oncology research is expected to propel the growth of market. For instance, in September 2018, U.S. FDA granted over US$ 18 million for new clinical trial research; out of which 33% is for rare forms of cancer, including advanced pancreatic cancer, head and neck squamous cell carcinoma, and acute myeloid leukemia.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Oncology Drug Pipeline Analysis Market Set Explosive Growth to 2026 By Key Companies F. Hoffmann-La Roche, Bristol-Myers Squibb, Johnson & Johnson, AstraZeneca here

News-ID: 1758856 • Views: 1043

More Releases from Coherent Market Insights - Pharmaceutical Industry

Radiopharmaceuticals in Nuclear Medicine Market Advancements to Watch Out For 20 …
Coherent Market Insights released a new market study on 2018-2026 Radiopharmaceuticals Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. Ask For Sample Copy of Research
Outsourced Drug Discovery Market: Latest Advancements & Market Outlook 2019 to 2 …
Outsourced drug discovery is a contract-based process, which is conducted by the contract research organizations (CRO) and contract manufacturing organization (CMO). Contract research organization provides support to pharmaceutical, biotechnology, and medical device industries for drug discovery and development. CRO facilitates the various services such as biopharmaceutical development, biologic assay development, preclinical research, clinical trials, and pharmacovigilance, for drug discovery and development. Ask For a Sample Copy of This Business Report @
Cannabis Testing Services Market: New Business Opportunities and Investment Rese …
Cannabis market is highly influenced by rigorous legalization efforts, which are aiming for approval of cannabis for medicinal or recreational purpose. Various governments and regulatory authorities are taking efforts to legalize cannabis, owing to its medicinal benefits. Moreover, commercialization of cannabis-based products under the legalized standards require successful cannabis testing, which further results in lucrative growth opportunity for market players. Ask For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2976 Market
Global Myelodysplastic Syndrome (MDS) Treatment Market Balenced To Reach Insigni …
Myelodysplastic syndrome (MDS) is a disorder, which affects the bone marrow and produces immature blood cells. Bone marrow failure leads to lowering the levels of healthy blood cells circulation in the bloodstream. According to Seattle Cancer Care Alliance, around 80%-85% of people with MDS have more cells in their bone marrow than healthy people. According to National Organization for Rare Disorders, MDS deteriorates into a form of cancer in around

All 5 Releases


More Releases for Oncology

Immuno Oncology Assays Market Size, Immuno Oncology Assays Market Prediction, Im …
The Immuno Oncology Assays Market Report examines the Immuno Oncology Assays industry from a variety of angles, including market size, status, trends, and forecasts. It also gives a quick rundown of the top competitors and development opportunities in the market. The research contains a comprehensive study of the keyword market, split by companies, regions, types, and applications. The research goes into great detail on several aspects that have been studied as
Global Oncology Biosimilars Market | Global Oncology Biosimilars Industry | Onco …
The oncology biosimilars market involves of sales of medicine and drug interrelated products for cancer treatment. Biosimilars are pharmaceuticals which are produced using cell lines and are fashionable to the manufacturer. The manufacturing of such cell line processes is a multipart and time-consuming procedure. According to the report analysis, ‘Oncology Biosimilars Market Global Report 2020-30’ states that the worldwide oncology biosimilars market was worth USD 2990.34 million in 2019. It is
International Oncology Summit
Allied Academies invites all the participants from all over the world to attend 'International Oncology Summit’ during November 27-28, 2017 in Atlanta, Georgia, USA which includes prompt keynote presentations, Poster presentations and Exhibitions. This Summit has the platform to fulfill the prevailing gaps in the transformation of this science of hope, to serve promptly with solutions to all in the need. Allied Academies was founded by Jim and JoAnn Carland and
International Oncology Summit
Allied Academies invites all the participants from all over the world to attend 'International Oncology Summit’ during November 27-28, 2017 in Atlanta, Georgia, USA which includes prompt keynote presentations, Poster presentations and Exhibitions. This Summit has the platform to fulfill the prevailing gaps in the transformation of this science of hope, to serve promptly with solutions to all in the need. Allied Academies was founded by Jim and JoAnn Carland and
International Oncology Summit
Allied Academies invites all the participants from all over the world to attend 'International Oncology Summit’ during November 27-28, 2017 in Atlanta, Georgia, USA which includes prompt keynote presentations, Poster presentations and Exhibitions. This Summit has the platform to fulfill the prevailing gaps in the transformation of this science of hope, to serve promptly with solutions to all in the need. Allied Academies was founded by Jim and JoAnn Carland and
International Oncology Summit
Allied Academies invites all the participants from all over the world to attend 'International Oncology Summit’ during November 27-28, 2017 in Atlanta, Georgia, USA which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions. This Summit has the platform to fulfill the prevailing gaps in the transformation of this science of hope, to serve promptly with solutions to all in the need. International Oncology Summit will have an anticipated